26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Pregnancy increases the risk of malaria and this is associated with poor health outcomes for both the mother and the infant, especially during the first or second pregnancy. To reduce these effects, the World Health Organization recommends that pregnant women living in malaria endemic areas sleep under insecticide-treated bednets, are treated for malaria illness and anaemia, and receive chemoprevention with an effective antimalarial drug during the second and third trimesters.

          Objectives

          To assess the effects of malaria chemoprevention given to pregnant women living in malaria endemic areas on substantive maternal and infant health outcomes. We also summarised the effects of intermittent preventive treatment with sulfadoxine-pyrimethamine (SP) alone, and preventive regimens for Plasmodium vivax.

          Search methods

          We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, and reference lists up to 1 June 2014.

          Selection criteria

          Randomized controlled trials (RCTs) and quasi-RCTs of any antimalarial drug regimen for preventing malaria in pregnant women living in malaria-endemic areas compared to placebo or no intervention. In the mother, we sought outcomes that included mortality, severe anaemia, and severe malaria; anaemia, haemoglobin values, and malaria episodes; indicators of malaria infection, and adverse events. In the baby, we sought foetal loss, perinatal, neonatal and infant mortality; preterm birth and birthweight measures; and indicators of malaria infection. We included regimens that were known to be effective against the malaria parasite at the time but may no longer be used because of parasite drug resistance.

          Data collection and analysis

          Two review authors applied inclusion criteria, assessed risk of bias and extracted data. Dichotomous outcomes were compared using risk ratios (RR), and continuous outcomes using mean differences (MD); both are presented with 95% confidence intervals (CI). We assessed the quality of evidence using the GRADE approach.

          Main results

          Seventeen trials enrolling 14,481 pregnant women met our inclusion criteria. These trials were conducted between 1957 and 2008, in Nigeria (three trials), The Gambia (three trials), Kenya (three trials), Mozambique (two trials), Uganda (two trials), Cameroon (one trial), Burkina Faso (one trial), and Thailand (two trials). Six different antimalarials were evaluated against placebo or no intervention; chloroquine (given weekly), pyrimethamine (weekly or monthly), proguanil (daily), pyrimethamine-dapsone (weekly or fortnightly), and mefloquine (weekly), or intermittent preventive therapy with SP (given twice, three times or monthly). Trials recruited women in their first or second pregnancy (eight trials); only multigravid women (one trial); or all women (eight trials). Only six trials had adequate allocation concealment.

          For women in their first or second pregnancy, malaria chemoprevention reduces the risk of moderate to severe anaemia by around 40% (RR 0.60, 95% CI 0.47 to 0.75; three trials, 2503 participants, high quality evidence), and the risk of any anaemia by around 17% (RR 0.83, 95% CI 0.74 to 0.93; five trials,, 3662 participants, high quality evidence). Malaria chemoprevention reduces the risk of antenatal parasitaemia by around 61% (RR 0.39, 95% CI 0.26 to 0.58; seven trials, 3663 participants, high quality evidence), and two trials reported a reduction in febrile illness ( low quality evidence). There were only 16 maternal deaths and these trials were underpowered to detect an effect on maternal mortality ( very low quality evidence).

          For infants of women in their first and second pregnancies, malaria chemoprevention probably increases mean birthweight by around 93 g (MD 92.72 g, 95% CI 62.05 to 123.39; nine trials, 3936 participants, moderate quality evidence), reduces low birthweight by around 27% (RR 0.73, 95% CI 0.61 to 0.87; eight trials, 3619 participants, moderate quality evidence), and reduces placental parasitaemia by around 46% (RR 0.54, 95% CI 0.43 to 0.69; seven trials, 2830 participants, high quality evidence). Fewer trials evaluated spontaneous abortions, still births, perinatal deaths, or neonatal deaths, and these analyses were underpowered to detect clinically important differences.

          In multigravid women, chemoprevention has similar effects on antenatal parasitaemia (RR 0.38, 95% CI 0.28 to 0.50; three trials, 977 participants, high quality evidence)but there are too few trials to evaluate effects on other outcomes.

          In trials giving chemoprevention to all pregnant women irrespective of parity, the average effects of chemoprevention measured in all women indicated it may prevent severe anaemia (defined by authors, but at least < 8 g/L: RR 0.19, 95% CI 0.05 to 0.75; two trials, 1327 participants, low quality evidence), but consistent benefits have not been shown for other outcomes.

          In an analysis confined only to intermittent preventive therapy with SP, the estimates of effect and the quality of the evidence were similar.

          A summary of a single trial in Thailand of prophylaxis against P. vivax showed chloroquine prevented vivax infection (RR 0.01, 95% CI 0.00 to 0.20; one trial, 942 participants).

          Authors' conclusions

          Routine chemoprevention to prevent malaria and its consequences has been extensively tested in RCTs, with clinically important benefits on anaemia and parasitaemia in the mother, and on birthweight in infants.

          PLAIN LANGUAGE SUMMARY
          The effect of taking antimalarial drugs routinely to prevent malaria in pregnancy

          Pregnancy increases the risk of malaria and this is associated with poor health outcomes for both the mother and the infant, especially during the first or second pregnancy. For this reason, women are encouraged to try and prevent malaria infection during pregnancy by sleeping under mosquito bed-nets, and by taking drugs effective against malaria throughout pregnancy as chemoprevention.

          This Cochrane Review looked at all drug regimens compared to placebo. The review authors sought to summarise and quantify the overall effects of chemoprevention. Seventeen trials were included, all conducted between 1957 and 2008, and all but two in countries of Africa.

          For women in their first or second pregnancy, malaria chemoprevention prevents moderate to severe anaemia ( high quality evidence); and prevents malaria parasites being detected in the blood ( high quality evidence). It may also prevent malaria illness. We don't know if it prevents maternal deaths, as this would require very large studies to detect an effect.

          In their infants, malaria chemoprevention improves the average birthweight ( moderate quality evidence), and reduces the number of low birthweight infants ( moderate quality evidence). We are not sure if chemoprevention reduces mortality of babies in the first week, month and year, as again studies would need to be very large to show these effects.

          Related collections

          Most cited references87

          • Record: found
          • Abstract: not found
          • Article: not found

          Cochrane Handbook for Systematic Reviews of Interventions

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Quantifying the Number of Pregnancies at Risk of Malaria in 2007: A Demographic Study

            Introduction Malaria in pregnancy can have devastating consequences to a pregnant woman and the developing fetus, but comprehensive estimates of the annual number of women who become pregnant each year in malaria endemic areas and are therefore at risk of malaria are not available, particularly for Latin America and the Asia-Pacific regions. These figures are an important first step towards informing policy makers and for estimating the regional needs for therapeutic and disease prevention tools for malaria in pregnancy. The most cited global estimate is from the Roll Back Malaria Partnership, which states that “each year approximately 50 million women living in malaria endemic countries throughout the world become pregnant” [1]. However, an explanation of the methods used to derive these estimates is not provided. More comprehensive estimates exist for Africa and are provided by the Africa Regional Office (AFRO) of the World Health Organization (WHO) in their widely quoted strategic framework document for malaria prevention and control during pregnancy in the African region [2]. Their estimate of 24.6 million pregnancies at risk of malaria (predominantly P. falciparum), is based on the number of live born babies delivered in malarious areas of Africa in the year 2000 using a combination of malaria risk maps [3] and estimates of the number of live births from UNICEF [4]. A more recent estimate by the WHO states that “In Africa, 30 million women living in malaria endemic areas become pregnant each year” [5]. Estimates for outside of Africa are less clear, particularly for P. vivax. P. vivax is the most widely distributed human malaria parasite and co-occurs with P. falciparum in tropical areas but also occurs in temperate regions outside the limits of P. falciparum transmission. It is the major cause of malaria in much of Asia and Latin America [6],[7], and recent evidence has shown that P. vivax infections are far from benign and can result in significant morbidity in pregnant women with serious consequences for maternal and infant health [8]–[10]. Here we define a global estimate of the number of pregnancies at risk of P. falciparum and P. vivax malaria in 2007 by combining malaria spatial limits developed by the Malaria Atlas Project (MAP; www.map.ox.ac.uk), which define the total population at risk of malaria [11], with country-specific demographic data on women of childbearing age provided by the United Nations and published data on induced abortions and spontaneous pregnancy loss. Methods Data Sources The global limits of P. falciparum malaria The initial focus of the Malaria Atlas Project has been P. falciparum [12] due to its global epidemiological significance [13] and better prospects for its control and local elimination [14]. The global spatial limits of P. falciparum malaria transmission in 2007 have recently been mapped. This was done by triangulating data on transmission exclusion using biological rules based on temperature and aridity limits on the bionomics of locally dominant Anopheles vectors, data on nationally reported case incidence rates, and other medical intelligence [15]. The resulting map stratifies the malaria endemic world by stable and unstable transmission in 2007 [15]. Unstable transmission refers to areas where transmission is plausible biologically, but limited, with a clinical incidence of less than one case per 10,000 population per year. Stable transmission refers to areas with a minimum of one clinical case per 10,000 population per year [15]. The global limits of P. vivax malaria Initial attempts to map the limits of P. falciparum and P. vivax transmission were made by Guerra et al. [16],[17]. The resulting maps and “masks” (mapped areas that are filtered and excluded from analyses) used were later tested against the Malaria Atlas Project parasite prevalence database to assess their feasibility [18],[19]. This testing revealed that the accuracy to define areas of zero transmission risk due to very low population densities was limited because of the coarse spatial resolution of the initial map. Moreover, in the initial mapping [16],[17], a high density population mask was used on the basis of the assumption that no transmission occurs in areas where the population density is so high that conditions become unsuitable for transmission through the process of urbanization. However, recent analyses [19] provide evidence suggesting that high density population masks and urban extent maps should not be used to map zero risk because some transmission can occur in high density urban areas, although this is significantly lower than in rural areas [18],[19]. Therefore, for the current analyses, the P. vivax limits were redefined using the same methods as in Guerra et al. [16],[17], but without applying the population-based masks. Also, previously excluded P. vivax endemic countries have now been added after a more extensive review of the literature; these include Comoros, Djibouti, Madagascar, and Uzbekistan. This refinement of the spatial limits of transmission for P. vivax accounted for an approximate 19% increase in the population at risk (PAR) compared with previous estimates [16],[17], principally (18%) due to the inclusion of major cities. Gridded population data The Global Rural-Urban Mapping Project (GRUMP) alpha version provides gridded population counts and population density estimates for the years 1990, 1995, and 2000, both adjusted and unadjusted to the United Nations' national population estimates [11],[20]. The adjusted population counts for the year 2000 were projected to 2007 by applying national, medium variant, intercensal growth rates by country [21] using methods described previously [22]. Annual number of pregnancies per country The number of pregnancies was calculated as the sum of the number of live births, induced abortions, and spontaneous pregnancy loss (including miscarriages and stillbirths) in 2007. Live births The annual number of live births in 2007 was estimated per country using demographic data on the proportion of women of childbearing age (WOCBAs) within a population and the total fertility rates. The data were abstracted from the United Nations' national population estimates, which provide publicly accessible demographic information by year, age, sex, and country for Africa, Asia, and the Americas [23]. The number of WOCBAs in each country, defined as the mid-year resident number of women aged between 15 and 49y, was obtained for the years 2005 and 2010 (interim years are not available), and the number of WOCBAs for 2007 was calculated as the midpoint between the 2005 and 2010 estimates. The fraction of WOCBAs per country was then calculated as the number of WOCBAs in 2007 divided by the mid-year resident population at risk in 2007 (available by year). The total fertility rate (TFR) is an age-standardised measure of fertility and corresponds to the total number of children that would be born alive to a woman entering her childbearing years at age 15y if she lived to the end of her childbearing years (age 49y) and if her fertility during these 35 reproductive years was the same as the average woman of childbearing age. The total fertility rate divided by 35 is the average number of live births per WOCBA per year and when multiplied by 1,000 this is expressed as the rate of live births per 1,000 WOCBAs per year. Induced abortions, miscarriages, and stillbirth rates Subregional data on induced abortion rates were obtained from a recently published review that calculated the worldwide, regional, and subregional incidence of safe and unsafe abortions in women of child bearing age in 2003 by use of reports from official national reporting systems, nationally representative demographic health surveys, hospital data, other surveys, and published studies [24]. Country-specific information on stillbirth rates was abstracted from model-based estimates published by Stanton et al. [25] that derived data from vital registration, demographic and health surveys (DHS), and data from study reports integrated into a regression model. Regional estimates were used for three malaria endemic countries for which country-specific estimates were not available (French Guiana, Mayotte, and Timor-Leste). Country-specific data on miscarriages (spontaneous abortions) are not available. To calculate the proportion of pregnancies resulting in miscarriage, a method was applied that uses multipliers to work backwards from the (known) number of live births and induced abortions to recover the (unknown) underlying number of pregnancies that “produced” them, as described in detail previously [24],[26]–[28]. The method takes account of pregnancies that are terminated voluntarily during the period of risk for miscarriage and estimates the number of spontaneous pregnancy loss (stillbirths and miscarriages) as 10% of induced abortions plus 20% of live births. It is based on clinical studies of rates of pregnancy loss by gestational age that indicate that for each 100 induced abortions an additional ten clinically recognised pregnancies will have aborted spontaneously prior to the average gestational age of induced abortions in that population, and that approximately 120 additional clinically recognised pregnancies are required to “produce” 100 live births [27],[28]. For example, in Afghanistan it was estimated that in 2007 1.182 million live births occurred among a population of 27 million and a further 0.284 million induced abortions occurred. The number of spontaneous pregnancy losses (the sum of the number of stillbirths and miscarriages) was therefore estimated at 0.2×1,182 plus 0.1×0.284 = 0.265 million, and the total number of pregnancies as 1.731 million. The reported number of miscarriages used in this manuscript represents the number of spontaneous pregnancy losses calculated through the multiplier method as described above, minus the country-specific number of stillbirths obtained from the review by Stanton et al. [25]. The estimates provided in this study refer to clinically recognised pregnancies and do not take into account the potentially large but unknown rates of embryonic loss that may occur in the first 4–6 wk of gestation. Estimating the annual number of pregnancies exposed to malaria To obtain the total population at risk, the limits of stable and unstable P. falciparum transmission and the limits of P. vivax transmission described above were overlaid onto the Global Rural-Urban Mapping Project (GRUMP) alpha surface, projected to 2007. For every malaria endemic country of the world, the population within each set of limits was extracted, following approaches described previously [13]. The number of pregnancies at risk of malaria was then calculated from the total annual number of pregnancies estimated to have occurred in 2007 in the entire country multiplied by the fraction of the total resident population living within the spatial limits of malaria transmission in that country. Results Tables 1 and 2 provide a summary of the total population living within the global spatial limits of malaria transmission in 2007, and the corresponding number of total population, pregnancies, and live births, stratified by species and transmission patterns (within areas of assumed unstable and stable P. falciparum transmission), globally and by WHO region. 10.1371/journal.pmed.1000221.t001 Table 1 Demographic data for malaria endemic countries. WHORO Region n of MECs Total Population (Both Sexes)a WOCBAsa Total n of Pregnanciesb TPRc Pregnancy Rate per 1,000 WOCBAs§ Percentage Pregnancies Ending in: Live-births Still-births Spontaneous Abortions Induced Abortions AFRO 43 755 178 36 7.16 204 72.4% 2.3% 13.3% 11.9% EMRO/EURO 19 544 142 19 4.76 136 68.8% 2.3% 13.1% 15.8% AMRO 21 530 143 16 3.81 109 63.2% 0.9% 14.0% 22.0% SEARO/WPRO 19 3,327 881 91 3.62 103 62.4% 1.6% 13.1% 22.8% Global 102 5,157 1,343 162 4.23 121 65.5% 1.8% 13.3% 19.5% a Source: United Nations Development Program (in millions). b The total number of pregnancies is the sum of the number of live-births, stillbirths, spontaneous, and induced abortions (in millions). c The total pregnancy rate (TPR) and the annual pregnancy rate per 1,000 WOCBAs are weighted means per region and is for illustration purposes only. The number of pregnancies was derived directly as the sum of the national estimates within each region and globally. MEC, malaria endemic countries; WHORO, World Health Organization Regional Office. 10.1371/journal.pmed.1000221.t002 Table 2 Total population at risk of P. falciparum and/or P. vivax malaria by WHO regional office in 2007 (in millions) (percent of the population in malaria endemic countries at risk). WHORO Region P. falciparum Transmissiona P. vivax Transmissiona Any Species Stable Transmissionb Unstable Transmissionb Overall Overall Overall AFRO 599.9 (79.4) 8.4 (1.1) 607.8 (80.5) 73.2 (9.7) 615.4 (81.5) EMRO/EURO 89.8 (16.5) 101.7 (18.7) 190.9 (35.1) 285.1 (52.4) 343.9 (63.2) AMRO 41.2 (7.8) 50.2 (9.5) 91.4 (17.2) 96.2 (18.2) 138.2 (26.1) SEARO/WPRO 654.9 (19.7) 824.9 (24.8) 1479.3 (44.5) 2,722.3 (81.8) 2,770.1 (83.3) Global 1,385.8 (26.9) 985.1 (19.1) 2,369.4 (45.9) 3,176.9 (61.6) 3,867.6 (75.0) Similar tables with risk estimates by continent and by pregnancy outcome (live-birth, induced abortions, stillbirths, and miscarriages) are provided in Tables S1, S2, S3. a Includes countries where P. falciparum and P. vivax co-exist. b Stable transmission, ≥1 autochthonous P. falciparum cases per 10,000 people per annum; unstable transmission, <1 autochthonous P. falciparum cases per 10,000 people per annum [15]. MEC, malaria endemic countries; TPR, total pregnancy rate; WHORO, World Health Organization Regional Office. The compiled data showed that, globally, 125.2 million women living in areas with P. falciparum and/or P. vivax transmission became pregnant in 2007: 77.4 million (61.8%) in the countries that fall under the regional office of the WHO for the South East Asian (SEARO) and the Western Pacific Region (WPRO); 30.3 million (24.2%) in AFRO; 13.1 million (10.5%) in the Eastern Mediterranean and European Region (EMRO and EURO); and only 4.3 million (3.4%) in the American Region (AMRO) (Table 3). Figures 1 and 2 display the same analysis by species, but depicted by continent rather than by WHO region. Of the 125.2 million pregnancies, 82.6 million (66.0%) are estimated to result in live births; 48.8 million (63.0%), 22.1 million (72.7%), 9.0 million (68.8%), and 2.7 million (63.1%) in the SEARO/WPRO, AFRO, EMRO/EURO, and AMRO regions, respectively (Table 4). It illustrates that the proportional distribution of pregnancies at risk resulting in live births is slightly different from the distribution of total pregnancies at risk, primarily reflecting the differences in the proportion of pregnancies ending in induced abortions, which is much lower in the AFRO region (11.9%) compared to the global average in the malaria endemic countries of 19.5% [24]. 10.1371/journal.pmed.1000221.g001 Figure 1 Malaria risk map for P. falciparum and corresponding number of pregnancies in each continent in 2007. 10.1371/journal.pmed.1000221.g002 Figure 2 Malaria risk map for P. vivax and corresponding number of pregnancies in each continent in 2007. 10.1371/journal.pmed.1000221.t003 Table 3 Number of pregnancies at risk of P. falciparum and/or P. vivax malaria by WHO regional office in 2007 (in millions) (column %). WHORO Region P. falciparum Transmissiona P. vivax Transmissiona Any Species Stable Transmissionb Unstable Transmissionb Overall Overall Overall AFRO 29.6 (54.1) 0.4 (1.2) 30.0 (35.1) 3.6 (3.9) 30.3 (24.2) EMRO/EURO 4.0 (7.3) 4.2 (13.7) 8.2 (9.6) 10.4 (11.2) 13.1 (10.5) AMRO 1.4 (2.5) 1.6 (5.2) 3.0 (3.5) 2.9 (3.1) 4.3 (3.4) SEARO/WPRO 19.7 (36.1) 24.5 (79.9) 44.2 (51.8) 76.0 (81.8) 77.4 (61.8) Global 54.7 30.6 85.3 92.9 125.2 Similar tables with risk estimates by continent and by pregnancy outcome (live-birth, induced abortions, stillbirths, and miscarriages) are provided in Tables S1, S2, S3. a Includes countries where P. falciparum and P. vivax co-exist. b Stable transmission, ≥1 autochthonous P. falciparum cases per 10,000 people per annum; unstable transmission, <1 autochthonous P. falciparum cases per 10,000 people per annum [15]. MEC, malaria endemic countries; TPR, total pregnancy rate; WHORO, World Health Organization Regional Office. 10.1371/journal.pmed.1000221.t004 Table 4 Number of live-births born to pregnancies at risk of at risk of P. falciparum and/or P. vivax malaria by WHO regional office in 2007 (in millions) (column %). WHORO Region P. falciparum Transmissiona P. vivax Transmissiona Any Species Stable Transmissionb Unstable Transmissionb Overall Overall Overall AFRO 21.6 (56.7) 0.3 (1.3) 21.8 (37.4) 2.5 (4.3) 22.1 (26.7) EMRO/EURO 2.8 (7.3) 2.9 (14.1) 5.6 (9.7) 7.1 (12.0) 9.0 (10.9) AMRO 0.8 (2.2) 1.0 (5.0) 1.8 (3.2) 1.8 (3.1) 2.7 (3.3) SEARO/WPRO 12.9 (33.8) 16.1 (79.5) 28.9 (49.7) 48.0 (80.6) 48.8 (59.1) Global 38.0 20.2 58.2 59.5 82.6 Similar tables with risk estimates by continent and by pregnancy outcome (live-birth, induced abortions, stillbirths, and miscarriages) are provided in Tables S1, S2, S3. a Includes countries where P. falciparum and P. vivax co-exist. b Stable transmission, ≥1 autochthonous P. falciparum cases per 10,000 people per annum; unstable transmission, <1 autochthonous P. falciparum cases per 10,000 people per annum [15]. MEC, malaria endemic countries; TPR, total pregnancy rate; WHORO, World Health Organization Regional Office. P. falciparum Malaria Of the 125.2 million pregnancies defined above, 85.3 million occur in areas with P. falciparum transmission, 51.8% of them (44.2 million) are in the combined SEARO-WPRO regions and 35.1% (30.0 million) in the AFRO region. The remainder live in the EMRO-EURO (9.6%) and AMRO regions (3.5%) (Figure 3; Table 3). As expected, the top five ranked countries with the highest number of pregnancies at risk of P. falciparum malaria were the malaria endemic countries with the largest overall populations: India (28.2 million), Nigeria (6.5 million), Indonesia (4.4 million), Pakistan (3.7 million), and the Democratic Republic of the Congo (3.3 million). Overall, 64.1% of 85.3 million pregnancies at risk of P. falciparum malaria live in areas with assumed stable transmission (Figure 3). However, this varies widely by region; from 98.7% in the AFRO region to none in the EURO region. As depicted in Figure 3, 55.3% of the 44.2 million pregnancies at risk of P. falciparum in the WPRO/SEARO region occur in areas of very low and unstable transmission. 10.1371/journal.pmed.1000221.g003 Figure 3 Distribution of the number of pregnancies in areas with P. falciparum malaria in 2007 by WHO regions and the corresponding proportion living under stable versus unstable transmission. Blue, SEARO and WPRO; green, AFRO; orange, EMRO; red, AMRO. P. vivax Malaria Globally, an estimated 92.9 million pregnancies occurred in areas endemic for P. vivax in 2007 (including in areas where both P. falciparum and P. vivax co-exist) (Figure 2). The top five ranked countries include: India (32.9 million), China (21.2 million), Indonesia (6.3 million), Pakistan (5.8 million), and Bangladesh (4.7 million). In the WPRO/SEARO region, where the majority of the populations at risk of P. vivax live (Figure 4), approximately 98.2% of those pregnancies in malaria endemic countries occur in areas with P. vivax transmission (alone or combined with P. falciparum). By contrast this was only 11.9% for the AFRO region where P. vivax transmission is principally restricted to the horn of Africa region, Madagascar, and the Comoros islands (Figure 4). 10.1371/journal.pmed.1000221.g004 Figure 4 Distribution of the number of pregnancies in malaria endemic areas in 2007 by WHO regions and by species (P. vivax transmission only, P. falciparum transmission only or transmission of both species). Blue, SEARO and WPRO; green, AFRO; orange, EMRO; red, AMRO. Pv, P. vivax; Pf, P. falciparum. The country-specific demographic data and population at risk estimates (Table S1), as well as total pregnancies at risk and by specific pregnancy outcomes (live births, induced abortions, stillbirths, and miscarriages; Table S2) and summary estimates by other regional categories (continents instead of WHO regions; Table S3), are provided as supplemental information. In addition, information is provided illustrating which countries are included in the different WHO regions (also see Figure S1) [29]. In brief, all malaria endemic countries on the African continent fall under the Africa Regional Office (AFRO), with the exception of Djibouti, Somalia, and Sudan, which fall under the EMRO office. Discussion This is the first time, to our knowledge, that contemporary species-specific estimates of the annual number of pregnancies at risk of malaria globally have been made. Our findings suggest that in 2007 approximately 125 million pregnancies occurred in areas with P. falciparum and/or P. vivax transmission, resulting in 83 million live births; representing approximately 60% of all pregnancies globally. Approximately 85 million pregnancies occurred in areas with P. falciparum transmission and 93 million in areas with transmission of P. vivax transmission, of which about 53 million occurred in areas where both species co-exist. The pregnancies at risk estimates for P. falciparum and P. vivax in Africa (32 million [30 million in the WHO-AFRO region]) are consistent with the previous estimates by WHO (25–30 million). By contrast, the numbers at risk outside Africa are much higher (95 million) than previously estimated (25 million). Comparisons between the estimates produced in this study and the previous WHO estimates are made difficult because details of the methodology used by the WHO is not provided and it is not clear if they included all transmission areas or only areas with stable malaria transmission. Inclusion of only those areas with stable P. falciparum transmission in our study resulted in global risk estimates of just less than 55 million pregnancies, 31 million in Africa and 23 million in the other regions, i.e., very similar to the previous WHO estimates. However, the numbers of pregnancies at risk outside Africa increase almost 4-fold if areas with unstable P. falciparum transmission are included (clinical incidence <1 per 10,000 population/year) (30 million) and areas situated in the temperate regions outside the limits of P. falciparum transmission that have P. vivax transmission only (40 million) are also included. It is also not clear if the previous WHO estimates included pregnancies resulting in live births only or included adjustments for induced abortions or spontaneous pregnancy loss. Since only approximately two-thirds of all pregnancies result in live births, estimates that include all pregnancies are about one-third higher than estimates based on live births only. Although risk estimates are widely quoted figures, it is important to place them in perspective. The estimates provided here merely define the global distribution of pregnancies that occur within the global spatial limits of malaria transmission. These estimates therefore represent “any risk” of exposure to malaria during pregnancy, and do not represent the distribution of actual incidence or health burden on mothers and unborn babies, which is beyond the scope of this paper. More than half (71 million) of the 125 million pregnancies occur in areas with unstable P. falciparum transmission (31 million) or with transmission of P. vivax only (40 million), and the risk of acquiring malaria in these areas is extremely low. Thus, although these 71 million pregnancies represent more than 50% of the global number of pregnancies at risk, they may only contribute a small proportion to the number of infections in pregnancy. For example, if the actual incidence of malaria infection in these very low transmission areas is 1 in 10,000 per person-year (52 wk), and if the average pregnancy resulting in a live birth takes 38 wk from fertilisation to term, then 71 million pregnancies at risk may result in only 5,188 actual malaria infections, whereas in areas with infection rates of 1.36 or higher per person-year, all term pregnancies have been potentially exposed to malaria. Furthermore, the definition of stable transmission for P. falciparum used included all areas with more than one clinical case per 10,000 population per year. This included almost all pregnancies at risk in the AFRO Region (99% of the 30 million pregnancies at risk) and 25 million of the 95 million (26%) pregnancies in the other WHO regions. However, these stable transmission strata cover a very wide range of transmission intensities and the actual risk of infection to the 55 million individuals and the impact on maternal and infant health varies enormously within this range. At the higher end of the transmission spectrum, the majority of malaria infections in pregnancy remain asymptomatic or pauci-symptomatic, yet are a major cause of severe maternal anaemia and preventable low birth weight, especially in the first and second pregnancies. In areas with stable, but low transmission, and certainly in areas with unstable and exceptionally low transmission, infections can become severe in all gravidae groups because most women of childbearing age in these regions have low levels of pre-pregnancy and pregnancy-specific protective immunity to malaria [30]. The most recent version of the World Malaria Map [28] from the Malaria Atlas Project shows that 89% of the populations in stable P. falciparum areas outside Africa live in areas characterised by low malaria endemicity (defined as P. falciparum parasite rate in children 2–10 y of age of ≤5%). This total includes all of the stable P. falciparum transmission areas in the Americas, and 88% of the populations at risk in the Central and South-East Asia-Pacific region [31]. Our estimates do not take seasonality into account and include all pregnancies occurring throughout the year, whereas those pregnancies that occur outside of the transmission season may be at no risk, or very low risk of exposure. Our risk estimates for P. vivax are likely to be less accurate than those for P. falciparum because of greater uncertainties about the basic biology of transmission and clinical epidemiology. For example, the climatic constraints on P. vivax transmission are less well defined, the accuracy of clinical reporting of P. vivax in areas with coincidental P. falciparum is poor, and the untreated hypnozoite stage of P. vivax, which can remain dormant in infected liver cells for months or years, provides an additional challenge to the interpretation of prevalence and incidence data [15]. We used a refined P. vivax risk map that resulted in a 19% increase over previous population at risk estimates (adjusted for population growth) [18],[19], principally resulting from the removal of the population density masks and thereby the inclusion of many large cities. In most of these cities, pregnancies will be at low or very low risk of autochthonous infections. Imported malaria associated with travel to rural areas may be a greater risk factor in these cities. We did not consider infections with P. ovale or P. malariae, as their distribution is not well described and the adverse effects on maternal health and the newborn infant are unknown. In the current analysis we used the map of the global spatial limits of P. falciparum malaria, which stratifies the malaria endemic world by stable and unstable transmission published in 2008 [15].This map uses a simple divide between very low risk and higher transmission intensities and a crude proxy to account for the corresponding levels of acquired immunity in women of childbearing age. As a next step, we will examine the burden of malaria in pregnancy in terms of health impact on the pregnant women (e.g., febrile episodes, impact on maternal anaemia and maternal mortality), the newborn baby (e.g., impact on the frequency of preterm births and low birth-weight) and the infant (e.g., susceptibility to malaria). For this project, we will use the more refined P. falciparum transmission intensity model of risk within the defined stable limits which was developed recently by the Malaria Atlas Project [31], allowing disease impact calculations across multiple transmission strata to be made. It is also important to take the different pregnancy outcomes into account in these further burden estimates. Of the 125 million pregnancies, one in five are estimated to be terminated voluntarily during the period of risk for miscarriage, and only about two-thirds (82.6 millions) are expected to result in live births. Although malaria in pregnancy is associated with miscarriages and stillbirths [30], the majority of the health and economic burden is likely through the impact on pregnancies that result in live births by increasing the risk of preterm births and low birth-weight [30] and by modifying the susceptibility to malaria in the infant [32]–[34]. Most of the existing research and policy guidance for malaria control in pregnancy has focussed on P. falciparum in the stable transmission regions of sub-Saharan Africa. The results of this study are consistent with the previous WHO-RBM risk estimates for areas with stable P. falciparum malaria in Africa, but our work offers advancement on the existing risk estimates for malaria endemic countries outside Africa. In these regions, the burden of malaria in pregnancy is less well defined, both in terms of the number of pregnancies and its actual impact on health. Policy guidelines for malaria control in pregnancy are also less well developed for these regions. These estimates of the number of pregnancies at risk of malaria provide a first step towards a spatial map of the burden of malaria in pregnancy and a more informed platform with which to estimate the associated disease and economic impact and its geographical distribution. Such global estimates provide guidance in terms of priority setting for resource allocation for both research and policy for the control of malaria in pregnancy. This project provides a dynamic framework that allows risk estimates to be updated when new risk maps of P. falciparum and P. vivax become available as the world attempts to move towards malaria elimination and eradication. Supporting Information Figure S1 Map of the WHO Regions (http://www.who.int/about/regions/en/index.html). (1.07 MB TIF) Click here for additional data file. Table S1 Demographic characteristics and total population at risk of P. falciparum and/or P. vivax malaria by malaria endemic country and by WHO regional office in 2007 (in millions). (0.38 MB PDF) Click here for additional data file. Table S2 Total number of pregnancies by pregnancy outcome in areas with P. falciparum and/or P. vivax transmission by continent in 2007 (in millions). (0.54 MB PDF) Click here for additional data file. Table S3 Total population, number of pregnancies, and number of live-births born to pregnancies in malaria endemic countries by continent in 2007 (in millions). (0.28 MB PDF) Click here for additional data file.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Guidelines for the treatment of malaria

              (2015)
                Bookmark

                Author and article information

                Journal
                Cochrane Database Syst Rev
                Cochrane Database Syst Rev
                cd
                The Cochrane Database of Systematic Reviews
                John Wiley & Sons, Ltd (Chichester, UK )
                1469-493X
                10 October 2014
                : 10
                : 1-120
                Affiliations
                [1 ]Child & Reproductive Health Group, Liverpool School of Tropical Medicine Liverpool, UK
                [2 ]University of Sciences, Techniques, and Technologies of Bamako Bamako, Mali
                [3 ]Department of Clinical Sciences, Liverpool School of Tropical Medicine Liverpool, UK
                Author notes
                Contact address: Paul Garner, Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK. paul.garner@ 123456lstmed.ac.uk .

                Editorial group: Cochrane Infectious Diseases Group.

                Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 10, 2014.

                Review content assessed as up-to-date: 1 June 2014.

                Article
                10.1002/14651858.CD000169.pub3
                4498495
                25300703
                1a5b9531-78d8-4289-ae23-2a7e2fe34252
                Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
                History
                Categories
                Review

                Comments

                Comment on this article